Yao Zhao

Yao Zhao

Auto-generated profile, based on publicly available information

Yao Zhao

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2015 in Cell Research
Verified
Journal Article
Open access
PDF file
ZMZeng-Yi Ma
Zeng-Yi Ma
ZSZhi-Jian Song
Zhi-Jian Song
JCJian-Hua Chen
Jian-Hua Chen
YWYong-Fei Wang
Yong-Fei Wang
SLShi-Qi Li
Shi-Qi Li
YZYao Zhao
Yao Zhao
Cushing's disease, also known as adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (PAs) that cause excess cortisol production, accounts for up to 85% of corticotrophin-dependent Cushing's syndrome cases. However, the genetic alterations in this disease are unclear. Here, we performed whole-exome sequencing of DNA derived from 12 ACTH-secreting PAs and matched blood samples, which revealed three types of somatic mutations in a candidate gene, USP8 (encoding ubiquitin-specific protease 8), exclusively in exon 14 in 8 of 12 ACTH-secreting PAs. We further evaluated somatic USP8 mutations in additional 258 PAs by Sanger sequencing. Targeted sequencing further identified a total of 17 types of USP8 variants in 67 of 108 ACTH-secreting PAs (62.04%). However, none of these mutations was detected in other types of PAs (n = 150). These mutations aggregate within the 14-3-3 binding motif of USP8 and disrupt the interaction between USP8 and 14-3-3 protein, resulting in an elevated capacity to protect EGFR from lysosomal degradation. Accordingly, PAs with mutated USP8 display a higher incidence of EGFR expression, elevated EGFR protein abundance and mRNA expression levels of POMC, which encodes the precursor of ACTH. PAs with mutated USP8 are significantly smaller in size and have higher ACTH production than wild-type PAs. In surgically resected primary USP8-mutated tumor cells, USP8 knockdown or blocking EGFR effectively attenuates ACTH secretion. Taken together, somatic gain-of-function USP8 mutations are common and contribute to ACTH overproduction in Cushing's disease. Inhibition of USP8 or EGFR is promising for treating USP8-mutated corticotrophin adenoma. Our study highlights the potentially functional mutated gene in Cushing's disease and provides insights into the therapeutics of this disease.

27 September 2016 in Cell Research
Verified
Journal Article
Open access
PDF file
ZSZhi-Jian Song
Zhi-Jian Song
ZRZachary J Reitman
Zachary J Reitman
ZMZeng-Yi Ma
Zeng-Yi Ma
JCJian-Hua Chen
Jian-Hua Chen
QZQi-Lin Zhang
Qi-Lin Zhang
YZYao Zhao
Yao Zhao
Pituitary adenomas (PAs) are one of the most common intracranial tumors, which can result in significant morbidity and can cause mortality either by exerting central pressure effects from the pituitary mass or by secreting excessive pituitary hormones1. Depending on their capability to produce hormones, PAs are classified as clinically functioning and nonfunctioning (NF). Functioning PAs include 6 subtypes, characterized by hypersecretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH), gonadotropins including follicle stimulating hormone and luteinizing hormone (GT), thyrotropin (TSH) or multiple hormones (plurihormonal), respectively. We and other group recently reported the recurrent genetic mutations in ACTH-PAs2,3. Previous studies also identified genetic alterations in GH-PAs by whole-genome and -exome sequencing4,5 and in 7 NF-PAs by exome analysis6. Due to challenges in collection and preparation of PA samples, exome-wide sequencing of other subtypes, including the PRL-, GT-, TSH-, and plurihormonal PA subtypes, has not been reported yet. To provide a comprehensive genetic landscape of all 7 subtypes of PAs, we examined the somatic mutational landscape of 125 PAs, including 20 NF-PAs, 20 PRL-PAs, 20 GH-PAs, 20 ACTH-PAs, 20 GT-PAs, 10 TSH-PAs, and 15 plurihormonal PAs. Plurihormonal PAs in this series secreted GH+PRL (n = 11), GH+ACTH (n = 2), or GH+TSH (n = 2). The analysis of 20 ACTH-PAs included 12 tumor samples analyzed in our previous study2. The clinical characteristics of these patients are summarized in Supplementary information, Table S1A. The detailed methods are described in Supplementary information, Data S1 and Figure S1A. We identified 412 somatic mutations in 125 PAs (Supplementary information, Table S1B). This analysis confirmed a relatively low number of somatic mutations per tumor across all 7 PA subtypes (mean = 3.3 mutations per exome; Figure 1A)3,4,5,6. The predominant substitution was C>T/G>A transitions which accounted for 41% of all substitutions across all PA subtypes, followed by T>C/A>G transitions (23%), similar to other intracranial tumors (Supplementary information, Figure S1B). Recurrently-mutated genes are shown in Figure 1A. We confirmed mutations in G protein subunit α (GNAS), ubiquitin-specific protease 8 (USP8), Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1), and Menin 1 (MEN1) in PAs and identified new somatic variants in these genes. Activating mutations of GNAS have long been known to play a role in pathogenesis of GH-PAs7. In this study, GNAS mutations were identified in 54% of all GH-secreting tumors, including 8 of 20 GH-monosecreting tumors and 11 of 15 plurihormonal tumors that secreted GH and another hormone. The high frequency of GNAS mutations in GH-PAs is consistent with previous findings4. GNAS alterations included p.R201C (n = 14), p.R201H (n = 1), p.Q227L (n = 3) and a novel p.G49R (n = 1) mutation. USP8 is a deubiquitinating enzyme that protects growth factor receptors including EGFR from degradation. Highly frequent USP8 mutations in ACTH-PAs have been shown by our group and others2,3. In this study, USP8 mutations were identified in 11 out of 20 ACTH-PAs, among which all mutation types have been described previously2,3. We also identified novel truncation mutations in the glucocorticoid receptor gene NR3C1 in two ACTH-PAs that did not contain USP8 mutations: p.Q632X-p.S512fs and p.R714P-p.630_630del. This is consistent with previous findings implicating mutations targeting NR3C1 as an uncommon contributor to ACTH-PA pathogenesis2. We additionally identified two novel somatic loss-of-function mutations in MEN1, including c.208_214del:p.D70fs and c.G608A:p.W203X, both in plurihormonal PAs producing GH and PRL from patients without a history of familial MEN syndrome and without germline MEN1 mutations. While germline MEN1 mutations have long been linked to PAs, MEN1 mutations have also been reported as rare somatic events in sporadic PAs8. We also identified recurrently-mutated kinesin heavy chain isoform 5A (KIF5A) and growth factor receptor-bound protein 10 (GRB10) as novel targets in two PA patients, respectively. KIF5A is a member of the kinesin family of proteins, which participates in a multisubunit complex to promote intracellular organelle transport. Somatic KIF5A mutations are found in prostate cancer9, but had not been linked to PAs. We identified somatic mutations targeting the stalk (p.Y749C) and tail (p.T938I) domains of KIF5A in two PAs. GRB10 encodes an intracellular adapter protein which interacts with several receptor tyrosine kinases and downstream signaling molecules to regulate secretion of insulin and other peptides10. We identified novel mutations in GRB10 including p.L357F and p.T155S, both in GH-PAs (2 out of 20 GH-PAs, 10%), one of which also contained a GNAS mutation, while the other one did not. GRB10 mutations in GH-PAs implicate GRB10 in the pathogenesis of GH-PAs. In addition, mutations of other genes, such as IARS, SP100 and TRIP12, occurred in two cases (Figure 1A). We next focused on somatic copy number alternations (SCNA) in our panel of 125 PAs (Supplementary information, Figure S1C). We found that 18% (22/125) of samples had SCNA involving < 10% of the genome; and 32% (40/125) had considerably greater levels of genomic disruption, with > 80% of the genome involved. We observed frequent loss of chromosomes 11q13.2 (q-value = 1.01E-18) and 11p15.5 (q-value = 1.14E-16), consistent with the previous study11. We also observed loss of 1p36.31 (q-value = 1.0098E-18), 9q34.11 (q-value = 2.39E-18), 16p13.3 (q-value = 5.82E-18), and 3p21.31 (q-value = 1.34E-17), and frequent gain of 20q13.33 (q-value = 1.47E-29), 3p22.3 (q-value = 3.10E-22), 1q31.3 (q-value = 5.06E-18), 7q21.11 (q-value = 1.54E-17), and 16q12.2 (q-value = 2.59E-21). Our copy number data revealed frequent gains in regions encoding cohesin complex genes including synaptonemal complex genes SYCP1 on...

9 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJianhua Chen
Jianhua Chen
XJXuemin Jian
Xuemin Jian
SDSiyu Deng
Siyu Deng
ZMZengyi Ma
Zengyi Ma
XSXuefei Shou
Xuefei Shou
Yongyong ShiYongyong Shi
Yongyong Shi
Cushing’s disease results from corticotroph adenomas of the pituitary that hypersecrete adrenocorticotropin (ACTH), leading to excess glucocorticoid and hypercortisolism. Mutations of the deubiquitinase gene USP8 occur in 35–62% of corticotroph adenomas. However, the major driver mutations in USP8 wild-type tumors remain elusive. Here, we report recurrent mutations in the deubiquitinase gene USP48 (predominantly encoding p.M415I or p.M415V; 21/91 subjects) and BRAF (encoding p.V600E; 15/91 subjects) in corticotroph adenomas with wild-type USP8. Similar to USP8 mutants, both USP48 and BRAF mutants enhance the promoter activity and transcription of the gene encoding proopiomelanocortin (POMC), which is the precursor of ACTH, providing a potential mechanism for ACTH overproduction in corticotroph adenomas. Moreover, primary corticotroph tumor cells harboring BRAF V600E are sensitive to the BRAF inhibitor vemurafenib. Our study thus contributes to the understanding of the molecular mechanism of the pathogenesis of corticotroph adenoma and informs therapeutic targets for this disease.

28 October 2022 in Cell Research
Verified
Journal Article
Open access
PDF file
FZFan Zhang
Fan Zhang
QZQilin Zhang
Qilin Zhang
JZJiajun Zhu
Jiajun Zhu
BYBoyuan Yao
Boyuan Yao
CMChi Ma
Chi Ma
YZYao Zhao
Yao Zhao
Pituitary neuroendocrine tumor (PitNET) is one of the most common intracranial tumors. Due to its extensive tumor heterogeneity and the lack of high-quality tissues for biomarker discovery, the causative molecular mechanisms are far from being fully defined. Therefore, more studies are needed to improve the current clinicopathological classification system, and advanced treatment strategies such as targeted therapy and immunotherapy are yet to be explored. Here, we performed the largest integrative genomics, transcriptomics, proteomics, and phosphoproteomics analysis reported to date for a cohort of 200 PitNET patients. Genomics data indicate that GNAS copy number gain can serve as a reliable diagnostic marker for hyperproliferation of the PIT1 lineage. Proteomics-based classification of PitNETs identified 7 clusters, among which, tumors overexpressing epithelial-mesenchymal transition (EMT) markers clustered into a more invasive subgroup. Further analysis identified potential therapeutic targets, including CDK6, TWIST1, EGFR, and VEGFR2, for different clusters. Immune subtyping to explore the potential for application of immunotherapy in PitNET identified an association between alterations in the JAK1-STAT1-PDL1 axis and immune exhaustion, and between changes in the JAK3-STAT6-FOS/JUN axis and immune infiltration. These identified molecular markers and alternations in various clusters/subtypes were further confirmed in an independent cohort of 750 PitNET patients. This proteogenomic analysis across traditional histological boundaries improves our current understanding of PitNET pathophysiology and suggests novel therapeutic targets and strategies.

1 May 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
QZQilin Zhang
Qilin Zhang
CPCheng Peng
Cheng Peng
JSJianping Song
Jianping Song
YZYichao Zhang
Yichao Zhang
JCJianhua Chen
Jianhua Chen
YZYao Zhao
Yao Zhao

20 September 2022 in Cell Discovery
Verified
Journal Article
Open access
PDF file
QZQilin Zhang
Qilin Zhang
LFLijiang Fei
Lijiang Fei
RHRui Han
Rui Han
RHRuofan Huang
Ruofan Huang
YWYongfei Wang
Yongfei Wang
YZYao Zhao
Yao Zhao
Skull base chordoma (SBC) is a bone cancer with a high recurrence rate, high radioresistance rate, and poorly understood mechanism. Here, we profiled the transcriptomes of 90,691 single cells, revealed the SBC cellular hierarchies, and explored novel treatment targets. We identified a cluster of stem-like SBC cells that tended to be distributed in the inferior part of the tumor. Combining radiated UM-Chor1 RNA-seq data and in vitro validation, we further found that this stem-like cell cluster is marked by cathepsin L (CTSL), a gene involved in the packaging of telomere ends, and may be responsible for radioresistance. Moreover, signatures related to partial epithelial–mesenchymal transition (p-EMT) were found to be significant in malignant cells and were related to the invasion and poor prognosis of SBC. Furthermore, YL-13027, a p-EMT inhibitor that acts through the TGF-β signaling pathway, demonstrated remarkable potency in inhibiting the invasiveness of SBC in preclinical models and was subsequently applied in a phase I clinical trial that enrolled three SBC patients. Encouragingly, YL-13027 attenuated the growth of SBC and achieved stable disease with no serious adverse events, underscoring the clinical potential for the precision treatment of SBC with this therapy. In summary, we conducted the first single-cell RNA sequencing of SBC and identified several targets that could be translated to the treatment of SBC.